{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:31:06Z","timestamp":1773865866084,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Elevated levels of the mineralocorticoid hormone aldosterone are recognized as a modifiable contributor to the pathophysiology of select cardiovascular diseases due to left heart failure. In pulmonary arterial hypertension (PAH), pulmonary vascular remodelling induces right ventricular dysfunction and heart failure in the absence of left ventricular (LV) dysfunction. Hyperaldosteronism has emerged as a promoter of pulmonary vascular disease in experimental animal models of PAH; however, the extent to which hyperaldosteronism is associated with PAH in patients is unknown. Thus, the central aim of the current study is to determine if hyperaldosteronism is an unrecognized component of the PAH clinical syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Plasma aldosterone levels and invasive cardiopulmonary haemodynamic measurements were obtained for 25 patients referred for evaluation of unexplained dyspnoea or pulmonary hypertension. Compared with controls (n = 5), patients with PAH (n = 18) demonstrated significantly increased plasma aldosterone levels (1200.4 \u00b1 423.9 vs. 5959.1 \u00b1 2817.9 pg\/mL, P &amp;lt; 0.02), mean pulmonary artery pressure (21.4 \u00b1 5.0 vs. 45.5 \u00b1 10.4 mmHg, P &amp;lt; 0.002), and pulmonary vascular resistance (PVR) (1.41 \u00b1 0.6 vs. 7.3 \u00b1 3.8 Wood units, P &amp;lt; 0.003) without differences in LV ejection fraction or pulmonary capillary wedge pressure between groups. Among patients not prescribed PAH-specific pharmacotherapy prior to cardiac catheterization, a subgroup of the cohort with severe pulmonary hypertension, aldosterone levels correlated positively with PVR (r = 0.72, P &amp;lt; 0.02) and transpulmonary gradient (r = 0.69, P &amp;lt; 0.02), but correlated inversely with cardiac output (r = \u20130.79, P &amp;lt; 0.005).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data demonstrate a novel cardiopulmonary haemodynamic profile associated with hyperaldosteronism in patients: diminished cardiac output due to pulmonary vascular disease in the absence of LV heart failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjhf\/hfs173","type":"journal-article","created":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T23:44:29Z","timestamp":1351640669000},"page":"277-283","source":"Crossref","is-referenced-by-count":98,"title":["Plasma Aldosterone Levels are Elevated in Patients with Pulmonary Arterial Hypertension in the Absence of Left Ventricular Heart Failure: A Pilot Study"],"prefix":"10.1093","volume":"15","author":[{"given":"Bradley A.","family":"Maron","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, and the Department of Cardiology, Veterans Affairs Boston Healthcare System, West Roxbury , MA ,","place":["USA"]},{"name":"The Dyspnea Center at Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander R.","family":"Opotowsky","sequence":"additional","affiliation":[{"name":"Boston Adult Congenital Heart Program, Department of Cardiology, Children\u2019s Hospital Boston , MA ,","place":["USA"]},{"name":"The Dyspnea Center at Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Landzberg","sequence":"additional","affiliation":[{"name":"Boston Adult Congenital Heart Program, Department of Cardiology, Children\u2019s Hospital Boston , MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Loscalzo","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron B.","family":"Waxman","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]},{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"The Dyspnea Center at Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane A.","family":"Leopold","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"2026011921142474400_ejhfhfs173-bib-0001","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1074\/jbc.M809460200","article-title":"Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells","volume":"284","author":"Maron","year":"2009","journal-title":"J Biol Chem"},{"key":"2026011921142474400_ejhfhfs173-bib-0002","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm1545","article-title":"Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity","volume":"13","author":"Leopold","year":"2007","journal-title":"Nat Med"},{"key":"2026011921142474400_ejhfhfs173-bib-0003","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"key":"2026011921142474400_ejhfhfs173-bib-0004","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Eng J Med"},{"key":"2026011921142474400_ejhfhfs173-bib-0005","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide level and modulate pulmonary arterial hypertension","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"key":"2026011921142474400_ejhfhfs173-bib-0006","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 Expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026011921142474400_ejhfhfs173-bib-0007","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.109.895235","article-title":"Aldosterone receptor antagonists: effective but often forgotten","volume":"121","author":"Maron","year":"2010","journal-title":"Circulation"},{"key":"2026011921142474400_ejhfhfs173-bib-0008","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.4081\/rt.2011.e45","article-title":"A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male","volume":"3","author":"Wanta","year":"2011","journal-title":"Rare Tumors"},{"key":"2026011921142474400_ejhfhfs173-bib-0009","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0895-7061(97)00301-4","article-title":"Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subject with essential hypertension","volume":"10","author":"Blacher","year":"1997","journal-title":"Am J Hypertens"},{"key":"2026011921142474400_ejhfhfs173-bib-00010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/01.CIR.103.1.72","article-title":"Aldosterone production is activated in failing ventricles in humans","volume":"103","author":"Mizuno","year":"2001","journal-title":"Circulation"},{"key":"2026011921142474400_ejhfhfs173-bib-00011","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0735-1097(94)90001-9","article-title":"Prognostic value of neurohormonal activation in patients with acute myocardial infarction: effect of captopril","volume":"24","author":"Rouleau","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"2026011921142474400_ejhfhfs173-bib-00012","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","article-title":"High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-segment myocardial infarction","volume":"114","author":"Beygui","year":"2006","journal-title":"Circulation"},{"key":"2026011921142474400_ejhfhfs173-bib-00013","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Eng J Med"},{"key":"2026011921142474400_ejhfhfs173-bib-00014","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011921142474400_ejhfhfs173-bib-00015","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/eurjhf\/hfq087","article-title":"Rationale and design of the \u2018aldosterone receptor blockade in diastolic heart failure\u2019 trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF)","volume":"12","author":"Edelmann","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011921142474400_ejhfhfs173-bib-00016","article-title":"Aldosterone receptor blockade I diastolic heart failure: the Aldo-DHF trial (Abstract)","author":"Edelmann","year":"2012","journal-title":"European Heart Society Meeting"},{"key":"2026011921142474400_ejhfhfs173-bib-00017","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201203-0411OC","article-title":"Dysregulated renin\u2013angiotensin\u2013aldosterone system contributes to pulmonary arterial hypertension","author":"de Man","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026011921142474400_ejhfhfs173-bib-00018","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1253\/jcj.46.1095","article-title":"Is captopril effective in primary pulmonary hypertension?","volume":"46","author":"Kokubu","year":"1982","journal-title":"Jpn Circ J"},{"key":"2026011921142474400_ejhfhfs173-bib-00019","first-page":"33","article-title":"[Activity of renin\u2013angiotensin\u2013aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension]","volume":"70","author":"Martyniuk","year":"1998","journal-title":"Ter Arkh"},{"key":"2026011921142474400_ejhfhfs173-bib-00020","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1172\/JCI105249","article-title":"Metabolism of aldosterone in several experimental situations with altered aldosterone secretion","volume":"44","author":"Davis","year":"1965","journal-title":"J Clin Invest"},{"key":"2026011921142474400_ejhfhfs173-bib-00021","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1378\/chest.125.1.112","article-title":"Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea","volume":"125","author":"Calhoun","year":"2004","journal-title":"Chest"},{"key":"2026011921142474400_ejhfhfs173-bib-00022","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo-and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"2026011921142474400_ejhfhfs173-bib-00023","article-title":"Blockade of renin\u2013angiotensin\u2013aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials","author":"Khatib","year":"2012","journal-title":"Int J Cardiol"},{"key":"2026011921142474400_ejhfhfs173-bib-00024","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1681\/ASN.2011080842","article-title":"The circadian clock modulates renal sodium handling","volume":"23","author":"Nikolaeva","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2026011921142474400_ejhfhfs173-bib-00025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/HJH.0b013e32833f5de5","article-title":"Role of CYP2C9 genetic variants for salt sensitivity and the regulation of the renin\u2013angiotensin\u2013aldosterone system in normotensive men","volume":"29","author":"Bolbrinker","year":"2011","journal-title":"J Hypertens"},{"key":"2026011921142474400_ejhfhfs173-bib-00026","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","article-title":"Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy","volume":"10","author":"Farquharson","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"2026011921142474400_ejhfhfs173-bib-00027","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1161\/01.CIR.83.6.1880","article-title":"Pathogenesis of edema in constrictive pericarditis. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones before and after pericardiectomy","volume":"83","author":"Anand","year":"1991","journal-title":"Circulation"},{"key":"2026011921142474400_ejhfhfs173-bib-00028","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/01.CIR.86.1.12","article-title":"Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery","volume":"86","author":"Anand","year":"1992","journal-title":"Circulation"},{"key":"2026011921142474400_ejhfhfs173-bib-00029","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ahj.2004.10.030","article-title":"Clinical correlation and prognostic predictive value of neurohumoral factors in patients late after the Fontan operation","volume":"150","author":"Inai","year":"2005","journal-title":"Am Heart J"},{"key":"2026011921142474400_ejhfhfs173-bib-00030","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1210\/jcem.82.10.4279","article-title":"Endothelin-1 stimulates steroid secretion of human adrenocortical cells ex vivo via both ETA and ETB receptor subtypes","volume":"82","author":"Rossi","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2026011921142474400_ejhfhfs173-bib-00031","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Eng J Med"},{"key":"2026011921142474400_ejhfhfs173-bib-00032","doi-asserted-by":"crossref","first-page":"L474","DOI":"10.1152\/ajplung.00202.2011","article-title":"Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension","volume":"302","author":"Johnson","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfs173","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1093%2Feurjhf%2Fhfs173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1093\/eurjhf\/hfs173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1093\/eurjhf\/hfs173","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/3\/277\/66443914\/eurjhf_15_3_277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/15\/3\/277\/66443914\/eurjhf_15_3_277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:17:08Z","timestamp":1768875428000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/15\/3\/277\/8428665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,1]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,1,27]]},"published-print":{"date-parts":[[2013,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjhf\/hfs173","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,3]]},"published":{"date-parts":[[2013,3,1]]}}}